Drug Trial Radar · NCT04655976
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
758
Actual
Start
Dec 8, 2020
Primary completion
Jun 5, 2025
Study completion Mar 30, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Dec 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.
Conditions
- Lung Cancer, Non-Small Cell
Interventions
CobolimabBiological
Cobolimab will be administered.
DostarlimabBiological
Dostarlimab will be administered.
DocetaxelDrug
Docetaxel will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) (Arm A Versus Arm C)Time frame: Up to approximately 234 weeks
- Overall Survival (OS) (Arm B Versus Arm C)Time frame: Up to approximately 234 weeks
Locations
163 sites in 24 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Fountain Valley, California
GSK Investigational Site
Walnut Creek, California
GSK Investigational Site
Norwich, Connecticut
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Honolulu, Hawaii
GSK Investigational Site
Iowa City, Iowa
GSK Investigational Site
Edgewood, Kentucky
GSK Investigational Site
Las Vegas, Nevada
GSK Investigational Site
Mineola, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
White Plains, New York
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Sioux Falls, South Dakota
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Fredericksburg, Virginia
GSK Investigational Site
Tacoma, Washington
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Cipoletti Rio Negro, Argentina
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina
GSK Investigational Site
Florida, Argentina
GSK Investigational Site
La Rioja, Argentina
GSK Investigational Site
Pergamino, Argentina
GSK Investigational Site
Rosario, Argentina
GSK Investigational Site
Viedma, Argentina
GSK Investigational Site
South Brisbane, Queensland, Australia
GSK Investigational Site
Ashford, South Australia, Australia
GSK Investigational Site
Hobart, Tasmania, Australia
GSK Investigational Site
Ballarat, Victoria, Australia
GSK Investigational Site
Melbourne, Victoria, Australia
GSK Investigational Site
Mount Waverley, Victoria, Australia
GSK Investigational Site
Aalst, Belgium
GSK Investigational Site
Hasselt, Belgium
GSK Investigational Site
Kortrijk, Belgium
GSK Investigational Site
Blumenau, Brazil
GSK Investigational Site
Fortaleza, Brazil
GSK Investigational Site
Porto Alegre, Brazil
GSK Investigational Site
Rio de Janeiro, Brazil
GSK Investigational Site
Rio de Janeiro, Brazil
GSK Investigational Site
Salvador, Brazil
Showing 40 of 163 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.